Five initial public offerings collectively raised $1.3 billion during the past week, bringing the year's total to 228 IPOs and $73.5 billion raised, a 35% increase over this time last year by deal count and an 84% increase by proceeds. The S&P 500 had the...read more
Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Atara Biotherapeutics plans to list on the NASDAQ under the...read more
Seven initial public offerings are expected to raise $1.7 billion in the upcoming week. Four IPOs are biotechs, including Forward Pharma, which could be the year's largest (and 60th), and three others in early stages of development. Consolidated fiber optic...read more
Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, announced terms for its IPO on Tuesday. The Brisbane, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14...read more
US IPO Weekly Recap: 5 IPOs achieve moderate gains during the market slide and a biotech rejection
Five initial public offerings collectively raised $1.3 billion during the past week, bringing the year's total to 228 IPOs and $73.5 billion raised, a 35% increase over this time last year by deal count and an 84% increase by proceeds. The S&P 500 had the...read more
Atara Biotherapeutics prices IPO at $11, below the range
Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Atara Biotherapeutics plans to list on the NASDAQ under the...read more
7 US IPOs planned for the week of October 13, including the IPO market's biotech test
Seven initial public offerings are expected to raise $1.7 billion in the upcoming week. Four IPOs are biotechs, including Forward Pharma, which could be the year's largest (and 60th), and three others in early stages of development. Consolidated fiber optic...read more
Atara Biotherapeutics refiles terms for $75 million IPO
Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, announced terms for its IPO on Tuesday. The Brisbane, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14...read more